Mirum Pharmaceuticals, Inc. (MIRM): M&A transaction — Mirum acquires Bluejay for $280.8M cash + stock; adds late-stage HDV therapy

Mirum Pharmaceuticals, Inc.

Upfront consideration $280.8M cash plus ~4.67M shares; holdback $25.8M plus ~0.52M shares; up to $200M milestones.
Added brelovitug (anti-HDV mAb) with FDA Breakthrough Therapy and EMA PRIME; Phase 3 AZURE topline data expected 2H 2026.
Concurrent private placements raised ~$268.5M gross proceeds to support brelovitug development and commercial activities.
Mirum also acquired Bluejay's net cash of ~$56.6M.
Entities affiliated with Frazier Life Sciences (board member >5% holder) received pro rata portion of consideration.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Mirum Pharmaceuticals, Inc. completed an acquisition involving Bluejay Therapeutics, Inc. for up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock (closed 2026-01-23).

Action: acquisition
Counterparty: Bluejay Therapeutics, Inc.
Consideration: up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock
Closing: 2026-01-23

Exact text from the filing

of the Mergers, the Company acquired Target’s net cash of approximately $56.6 million and paid or will pay to the holders of Target’s securities up to an aggregate amount of (i) $280.8 million in cash and (ii) 4,673,597 shares of Company common stock, subject to the Company’s receipt of deliverables that are a condition to payment and deduction to satisfy applicable

View on SEC.gov

Browse all m&a transactions →

Mirum Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-022582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.